AstraZeneca to Build $1.5 Billion Drug Plant in Singapore (1)

AstraZeneca Plc plans to build a $1.5 billion manufacturing facility in Singapore to make antibody-drug conjugates as the UK drugmaker pushes to beef up its ability to produce the next-generation cancer treatments.

The plant will be Astra’s first drug-conjugate facility to produce the medicines from start to finish, the company said in a statement Monday. It’s scheduled to open in 2029 and will emit zero carbon from the start.

Chief Executive Officer Pascal Soriotis working to ensure Astra can independently supply drugs to major markets as the US pushes to reduce the industry’s reliance on China. Shortages during ...